Apellis Pharmaceuticals, Inc. APLS shares are trading higher Thursday after the company reported preliminary U.S. third-quarter net product revenue for SYFOVRE.
What To Know: Apellis highlighted continued strong demand for SYFOVRE, with preliminary U.S. revenue of approximately $74 million in the third-quarter.
Furthermore, approximately 37,000 commercial vials and 10,000 samples were distributed to physician practices in the third-quarter and over 100,000 total vials have been delivered to date.
"In only seven months, more than 100,000 vials have been shipped to physician practices, which we believe is a testament to the unmet need and the strength of SYFOVRE's product profile. SYFOVRE offers increasing treatment effects over time with as few as six doses per year," said Adam Townsend, CEO, Apellis.
Related Link: Sensata's Shift To Electrification Has Hurdles, Analyst Cites $16M-$20M In Restructuring Costs
APLS Price Action: Shares of APLS were up 6.73% at $40.15 at the time of publication, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
